A simple solid-phase approach for the synthesis of DOTA-conjugated α-ketoamide-based fibroblast activation protein-targeted ligands
Bioorganic & Medicinal Chemistry Letters · 2026-09 · 138 · 130693
DOI: 10.1016/j.bmcl.2026.130693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2026-09. Verfasst von Shireen Jozi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada. Hauptthemen laut MEDLINE: Serine Endopeptidases, Heterocyclic Compounds, 1-Ring, Radiopharmaceuticals, Gelatinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: National Institutes of Health, National Institute of Allergy and Infectious Diseases, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Several studies have shown that fibroblast activation protein (FAP)-targeted radioligands with an α-ketoamide as the warhead can lead to high affinity for FAP and prolonged tumor retention. However, the preparation of reported FAP-targeted ligands requires multiple solution-phase synthesis and purification steps. Herein, we report a simple solid-phase approach for synthesizing DOTA-conjugated α-ketoamide-based FAP-targeted ligands. The new ligand, FAPI-CRC, was constructed on Rink Amide MBHA resin by sequentially coupling Fmoc-protected amino acids and DOTA-tris(tert-butyl ester), oxidation of α-hydroxyamide to α-ketoamide by 2-iodoxybenzoic acid in dimethyl sulfoxide, and final cleavage/deprotection with trifluoroacetic acid, followed by HPLC purification. FAPI-CRC was labeled with natGa/68Ga to investigate its ability to target FAP in vitro and in vivo, respectively. natGa-FAPI-CRC was obtained in 50% yield and [68Ga]Ga-FAPI-CRC was obtained in 27% decay-corrected radiochemical yield with >99% radiochemical purity and a molar activity of 30.8 GBq/μmol. FAPI-CRC and natGa-FAPI-CRC exhibited high affinity for FAP with IC50 values of 0.33 ± 0.09 and 0.42 ± 0.27 nM, respectively. Positron emission tomography (PET) imaging and ex vivo biodistribution studies in mice showed that [68Ga]Ga-FAPI-CRC was specifically taken up by HEK293T:hFAP tumor xenografts with good tumor-to-background contrast at 1 h post-injection. Therefore, our simple solid-phase approach is promising for the synthesis of potent α-ketoamide-based FAP-targeted ligands and can be used to greatly facilitate the development of radiopharmaceuticals for the management of FAP-expressing cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
- Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada; Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, BC V5Z 4E6, Canada; Department of Radiology…
Förderung
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- Canadian Institutes of Health Research
Zitieren
APA
Jozi, S., Ng, P., Merkens, H., Cookson, F., Bénard, F., & Lin, K. S. (2026). A simple solid-phase approach for the synthesis of DOTA-conjugated α-ketoamide-based fibroblast activation protein-targeted ligands. Bioorganic & Medicinal Chemistry Letters, 138, 130693. https://doi.org/10.1016/j.bmcl.2026.130693
Vancouver
Jozi S, Ng P, Merkens H, Cookson F, Bénard F, Lin KS. A simple solid-phase approach for the synthesis of DOTA-conjugated α-ketoamide-based fibroblast activation protein-targeted ligands. Bioorganic & Medicinal Chemistry Letters. 2026;138:130693. doi:10.1016/j.bmcl.2026.130693
BibTeX
@article{Jozi2026,
author = {Jozi, Shireen and Ng, Pauline and Merkens, Helen and Cookson, Finnley and Bénard, François and Lin, Kuo-Shyan},
title = {A simple solid-phase approach for the synthesis of DOTA-conjugated α-ketoamide-based fibroblast activation protein-targeted ligands},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2026},
volume = {138},
pages = {130693},
doi = {10.1016/j.bmcl.2026.130693}
}
EUVIMED